<DOC>
	<DOCNO>NCT01135186</DOCNO>
	<brief_summary>Kuvan速 ( sapropterin dihydrochloride ) Improving Gastric Accommodation Women Diabetic Gastroparesis ( KIGA-DG )</brief_summary>
	<brief_title>Impact KUVAN速 Gastric Relaxation Women With Diabetic Gastroparesis .</brief_title>
	<detailed_description>Patients invited participate research study Kuvan速 ( sapropterin dihydrochloride ) . We hope learn whether treatment Kuvan速 safe effective improve ability stomach relax eat improve symptom diabetic gastroparesis . Women select possible participant study diabetes moderate severe gastroparesis ( mean stomach empty slowly ) .</detailed_description>
	<mesh_term>Gastroparesis</mesh_term>
	<mesh_term>Verapamil</mesh_term>
	<criteria>Inclusion Criteria Patients moderate severe symptom diabetic gastroparesis study ( GCSI &gt; 21 ) . Patients postsurgical gastroparesis dyspeptic symptom normal gastric emptying . In order qualify inclusion trial , patient must satisfy follow inclusion criterion : 1 . Diagnosis diabetes mellitus &gt; 5 year require medical therapy 2 . Female gender 3 . Ages 1865 year 4 . Documentation delay gastric empty gastric empty scintigraphy ( within 2 year enrollment ) 5 . Symptoms gastroparesis least 6 month Gastroparesis Cardinal Symptom Index ( GCSI ) score &gt; 21 indicate moderate severe symptom 6 . Recent negative upper endoscopy upper GI series within 2 year enrollment ( evidence mechanical obstruction peptic ulcer disease ) Exclusion Criteria Patients satisfy follow exclusion criterion ineligible enrollment study : 1 . Diabetes diagnose &lt; 5 year prior study 2 . Male gender 3 . Normal gastric empty 4 . Gastroparesis postsurgical etiology 5 . Another active disorder , could explain symptoms opinion investigator 6 . Pregnancy 7 . History significant cardiac arrhythmia and/or prolong QTc 8 . Daily use narcotic analgesic abdominal pain 9 . Contraindications gastric empty breath test : patient know allergy egg , wheat , algae . 10 . Underlying seizure disorder 11 . Known history cardiac ischemia 12 . Recent clinically significant gastrointestinal bleeding 13 . Patients take Levodopa 14 . Any condition , opinion investigator would impede compliance hinder completion study 15 . Failure give inform consent 16 . Surgery placement gastric stimulator within past 6 month ( patient &gt; 6 month postop persistent symptom delay gastric empty eligible ) . 17 . A normal upper endoscopy perform within 2 year study entry . 18 . Patients take phosphodiesterase inhibitor sildenafil , vardenafil , tadalafil 19 . Patients renal impairment ( i.e . Creatinine &gt; 2.5 mg/dL ) 20 . Patients hepatic dysfunction ( i.e . ALT AST value &gt; 2.5x ULN T. bilirubin &gt; 1.5x ULN ) 21 . Patients uncontrolled diabetes , HbA1c &gt; 10 mg/dl screening/baseline exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>